



CLAIMS

1. A compound having the formula



wherein:

- 5 R¹ is oxo, -OR^a, -OC(=O)R^b; or



R² is H; or

R¹ is -OR^c and R² is -OR^d; or

R¹ and R² together form -O(CH₂)_mO-;

- 10 R³ is H or C₁₋₆alkyl;

R⁴ is independently selected from hydroxy, halo, C₁₋₆alkoxy, C₁₋₆alkyl, cyanoC₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carboxy, C₁₋₆alkoxy-carbonyl, carbamoyl, C₁₋₆alkylcarbamoyl, di-C₁₋₆alkylcarbamoyl, C₁₋₆alkanoyl, C₁₋₆alkanoylamino and aminosulfonyl;

- 15 R⁵ is independently selected from hydroxy, cyano, nitro, trifluoromethoxy, trifluoromethyl, C₁₋₆alkylsulfonyl, halo, C₁₋₆alkoxy, C₁₋₆alkyl, cyanoC₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carboxy, C₁₋₆alkoxy-carbonyl, carbamoyl, C₁₋₆alkylcarbamoyl, di-C₁₋₆alkylcarbamoyl, C₁₋₆alkanoyl, C₁₋₆alkanoylamino, aminosulfonyl, and substituted C₁₋₆alkyl; or

R⁴ and R⁵ together form -OCH₂O- or -OC(CH₃)₂O-;

- 20 R⁶ is selected from hydrogen, hydroxy, cyano, nitro, trifluoromethoxy, trifluoromethyl, C₁₋₆alkylsulfonyl, halo, C₁₋₆alkoxy, C₁₋₆alkyl, cyanoC₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carboxy, C₁₋₆alkoxy-carbonyl, carbamoyl, C₁₋₆alkylcarbamoyl, di-C₁₋₆alkylcarbamoyl, C₁₋₆alkanoyl, C₁₋₆alkanoylamino, aminosulfonyl, and substituted C₁₋₆alkyl

R⁷ is substituted phenyl;

R⁸ is selected from hydrogen, hydroxy, C₁₋₆alkoxy, C₁₋₆alkanoyloxy, C₁₋₆alkanoyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkanoylamino, C₁₋₆alkyl, carbamoyl, C₁₋₆alkylcarbamoyl, and bis(C₁₋₆alkyl)carbamoyl;

5 R^a is hydrogen or C₁₋₆alkyl;

R^b is C₁₋₆alkyl, aryl or arylC₁₋₆alkyl;

R^c and R^d are independently selected from C₁₋₆alkyl;

m is 2, 3, or 4; and

X¹ and X² are independently H or halogen, wherein at least one of X¹ and X² are

10 halogen; and

any pharmaceutically-acceptable salt thereof.


2. A compound according to Claim 1 wherein:

R¹ is oxo, -OR^a, or -OC(=O)R^b; or

15 R¹ is -OR^c and R² is -OR^d.

3. A compound according to Claim 1 wherein:

R¹ is



20 R² is H.

4. A compound according to Claim 3 wherein:

R⁷ is phenyl substituted in the ortho position by a substituent selected from C₁₋₆alkylthio, C₁₋₆alkylsulfinyl, C₁₋₆alkylsulfonyl, trifluoromethylthio, trifluoromethylsulfinyl, C₁₋₆alkanesulfonamido, C₁₋₆alkanoyl, C₁₋₆alkoxy-carbonyl, succinamido, carbamoyl, C₁₋₆alkylcarbamoyl, di-C₁₋₆alkylcarbamoyl, C₁₋₆alkoxy-C₁₋₆alkylcarbamoyl, C₁₋₆alkanoylamino, ureido, C₁₋₆ureido, di-C₁₋₆alkylureido, amino, C₁₋₆alkylamino and di-C₁₋₆alkylamino; and substituted in the para position by a substituent selected from

hydrogen, methyl, methoxy, acetyl, acetylamino, methoxycarbonyl, methanesulfonylamino, methyl-sulfinyl, methylsulfonyl, trifluoromethyl, trifluoromethylthio, trifluoromethylsulfinyl, bromo, fluoro, chloro, hydroxy, carbamoyl, methylcarbamoyl, dimethylcarbamoyl-methylureido and dimethylureido; and

- 5 R^8 is selected from hydrogen, hydroxy, methoxycarbonyl, methylcarbamoyl and dimethylcarbamoyl.

5. A compound according to Claim 4 wherein:


R^7 is methylsulfinyl, methylsulfonyl, methylureido, dimethylureido, amino,
10 methylamino or dimethylamino;

R^8 is hydroxy or hydrogen; and

R^9 is hydrogen, C_{1-6} alkoxy, halo, C_{1-6} alkylsulfinyl, or carboxy.

6. A compound according to Claim 5 wherein:

15 R^7 is



R^8 is hydrogen; and

R^9 is hydrogen, methoxy or fluoro.

- 20 7. A compound according to any of Claims 2, 3, 4, or 6 wherein:

R^3 is hydrogen, methyl or ethyl;

R^4 is C_{1-4} alkoxy, C_{1-4} alkyl, halogen, halo C_{1-2} alkoxy, halo C_{1-4} alkyl, $-\text{CH}=\text{CHCH}_3$,
-S(O) $_n$ CH $_3$, or -OS(O) $_2$ CH $_3$;

R^5 is cyano, nitrogen, hydrogen or halogen;

25 R^6 is hydrogen, methoxy, cyano or nitro; and

n is 0, 1 or 2.

8. A compound according to Claim 7 wherein:

R^3 is hydrogen, methyl or ethyl;


R^4 is methyl, ethyl, methoxy, ethoxy, hydroxy or fluoro;

R^5 is cyano or nitro; and

5 R^6 is hydrogen.


9. A process for preparing a compound according to Claim 3 which process comprises the step of:

10 reacting a compound of the formula (III) with a compound of the formula (IV) under reductive amination conditions:




wherein R^3 through R^8 , X^1 and X^2 are as in Claim 3; and L and L' are groups such that reductive amination of the compounds of the formulae (III) and (IV) forms a N-C bond; or

20 reacting a compound of the formula (V) with a compound of the formula (VI):



(V)



(VI)

wherein R^3 through R^8 , X^1 and X^2 are as defined in Claim 3; and L'' is a leaving group.

10. A pharmaceutical composition comprising a compound according to any one of Claims 1 through 8.

11. A method of treating depression, anxiety, asthma, rheumatoid arthritis, Alzheimer's disease, cancer, schizophrenia, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, anxiety, emesis, Huntington's disease, psychoses including depression, hypertension, migraine, bladder hypermotility, or urticaria comprising administering an effective amount of an NK1 antagonist according to any one of Claims 1 through 8.

add A2